Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) in a report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

A number of other research analysts also recently issued reports on VNDA. Cantor Fitzgerald boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Thursday, August 1st. HC Wainwright began coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a "buy" rating and a $18.00 price objective for the company.

Vanda Pharmaceuticals Trading Up 3.4 %

Shares of NASDAQ:VNDA traded up $0.17 on Friday, hitting $5.19. 831,245 shares of the company were exchanged, compared to its average volume of 1,307,844. The firm has a market capitalization of $302.53 million, a P/E ratio of -18.54 and a beta of 0.77. Vanda Pharmaceuticals has a 1-year low of $3.30 and a 1-year high of $6.75. The stock's 50 day moving average price is $4.79 and its 200 day moving average price is $5.24.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $47.65 million during the quarter, compared to analysts' expectations of $47.50 million. Vanda Pharmaceuticals had a negative return on equity of 3.01% and a negative net margin of 8.59%. On average, equities analysts predict that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Sei Investments Co. lifted its position in shares of Vanda Pharmaceuticals by 39.6% in the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company's stock valued at $2,132,000 after acquiring an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Vanda Pharmaceuticals during the 1st quarter worth $1,158,000. Acadian Asset Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 4.7% during the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company's stock worth $9,740,000 after buying an additional 107,203 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $1,090,000. Finally, Empowered Funds LLC lifted its stake in shares of Vanda Pharmaceuticals by 8.2% in the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company's stock worth $827,000 after buying an additional 15,215 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.